133 related articles for article (PubMed ID: 38142693)
1. Dolutegravir for second-line antiretroviral therapy: the beat goes on.
Shangase N; Kufa T
Lancet Glob Health; 2024 Feb; 12(2):e183-e184. PubMed ID: 38142693
[No Abstract] [Full Text] [Related]
2. Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy.
Dorward J; Sookrajh Y; Lessells R; Bulo E; Bodley N; Singh L; Moodley P; Samsunder N; Drain PK; Hayward G; Butler CC; Garrett N
J Acquir Immune Defic Syndr; 2024 Apr; 95(5):e8-e11. PubMed ID: 38489494
[TBL] [Abstract][Full Text] [Related]
3. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.
Dorward J; Lessells R; Drain PK; Naidoo K; de Oliveira T; Pillay Y; Abdool Karim SS; Garrett N
Lancet HIV; 2018 Jul; 5(7):e400-e404. PubMed ID: 29884404
[TBL] [Abstract][Full Text] [Related]
4. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
Turkova A; White E; Mujuru HA; Kekitiinwa AR; Kityo CM; Violari A; Lugemwa A; Cressey TR; Musoke P; Variava E; Cotton MF; Archary M; Puthanakit T; Behuhuma O; Kobbe R; Welch SB; Bwakura-Dangarembizi M; Amuge P; Kaudha E; Barlow-Mosha L; Makumbi S; Ramsagar N; Ngampiyaskul C; Musoro G; Atwine L; Liberty A; Musiime V; Bbuye D; Ahimbisibwe GM; Chalermpantmetagul S; Ali S; Sarfati T; Wynne B; Shakeshaft C; Colbers A; Klein N; Bernays S; Saïdi Y; Coelho A; Grossele T; Compagnucci A; Giaquinto C; Rojo P; Ford D; Gibb DM;
N Engl J Med; 2021 Dec; 385(27):2531-2543. PubMed ID: 34965338
[TBL] [Abstract][Full Text] [Related]
5. Increase in Body Mass Index in Children With HIV, Switched to Tenofovir Alafenamide Fumarate or Dolutegravir Containing Antiretroviral Regimens.
Yeoh DK; Campbell AJ; Bowen AC
Pediatr Infect Dis J; 2021 May; 40(5):e215-e216. PubMed ID: 33847305
[No Abstract] [Full Text] [Related]
6. Concerns and clarifications regarding the article 'Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first line ART regimen in Zimbabwe'.
Karabay O
AIDS; 2024 Jul; 38(8):1273. PubMed ID: 38814717
[No Abstract] [Full Text] [Related]
7. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
[TBL] [Abstract][Full Text] [Related]
8. Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/Abacavir.
Calza L; Legnani G; Fulgaro C; Verucchi G; Bon I; Lazzarotto T; Viale P
J Acquir Immune Defic Syndr; 2022 Mar; 89(3):e30. PubMed ID: 34743087
[No Abstract] [Full Text] [Related]
9. Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy.
Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Huang SH; Huang YC; Su YC; Liu WC; Hung CC
Int J Infect Dis; 2021 Apr; 105():147-151. PubMed ID: 33592339
[TBL] [Abstract][Full Text] [Related]
10. Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first-line antiretroviral therapy regimen in Zimbabwe.
Kouamou V; Washaya T; Mapangisana T; Ndhlovu CE; Manasa J
AIDS; 2024 Apr; 38(5):689-696. PubMed ID: 38227596
[TBL] [Abstract][Full Text] [Related]
11. Dolutegravir: first global approval.
Ballantyne AD; Perry CM
Drugs; 2013 Sep; 73(14):1627-37. PubMed ID: 24052331
[TBL] [Abstract][Full Text] [Related]
12. The promise of paediatric dolutegravir.
Golin R; Samuel JM; Phelps BR; Persaud U; Malati CY; Siberry GK
J Int AIDS Soc; 2021 Jan; 24(1):e25660. PubMed ID: 33522081
[No Abstract] [Full Text] [Related]
13. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
Viani RM; Ruel T; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Palumbo P; Buchanan AM; Vavro C; Singh R; Graham B; Anthony P; George K; Wiznia A;
J Pediatric Infect Dis Soc; 2020 Apr; 9(2):159-165. PubMed ID: 30951600
[TBL] [Abstract][Full Text] [Related]
14. Short-cycle therapy (5 days on/2 days off) with a lamivudine + dolutegravir regimen in a cohort of virologically suppressed patients with HIV infection.
Lanzafame M; Lattuada E; Gottardo R; Piacentini D; Be G; Razzaboni E; Cattaneo P; Luise D; Vento S
Int J Antimicrob Agents; 2021 Mar; 57(3):106290. PubMed ID: 33513407
[No Abstract] [Full Text] [Related]
15. Erratic enteric absorption of dolutegravir in a critically ill patient.
de Antonio-Cuscó M; Parrilla FJ; Knobel Freud H; Echeverría-Esnal D; Castellví Font A; Vázquez A; Masclans JR; Ferrández O; Grau S
Rev Esp Quimioter; 2022 Aug; 35(4):408-410. PubMed ID: 35644951
[No Abstract] [Full Text] [Related]
16. Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice.
Ciccullo A; Baldin G; Cossu MV; Passerini M; Borghetti A; Capetti A; Di Giambenedetto S
AIDS Res Hum Retroviruses; 2020 Jan; 36(1):4-5. PubMed ID: 31476877
[No Abstract] [Full Text] [Related]
17. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
Kanters S; Vitoria M; Doherty M; Socias ME; Ford N; Forrest JI; Popoff E; Bansback N; Nsanzimana S; Thorlund K; Mills EJ
Lancet HIV; 2016 Nov; 3(11):e510-e520. PubMed ID: 27658869
[TBL] [Abstract][Full Text] [Related]
18. Body Fat Distribution and Metabolic Changes in a Cohort of Adolescents Living With HIV Switched to an Antiretroviral Regimen Containing Dolutegravir.
Giacomet V; Lazzarin S; Manzo A; Paradiso L; Maruca K; Barera G; Zuccotti GV; Mora S
Pediatr Infect Dis J; 2021 May; 40(5):457-459. PubMed ID: 33847293
[TBL] [Abstract][Full Text] [Related]
19. HIV 101: fundamentals of antiretroviral therapy.
Saag MS
Top Antivir Med; 2019 Sep; 27(3):123-127. PubMed ID: 31634859
[TBL] [Abstract][Full Text] [Related]
20. Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy.
Gianella S; Marconi VC; Berzins B; Benson CA; Sax P; Fichtenbaum CJ; Wilkin T; Vargas M; Deng Q; Oliveira MF; Moser C; Taiwo BO
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):e112-e114. PubMed ID: 30383591
[No Abstract] [Full Text] [Related]
[Next] [New Search]